Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement .
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled
Kuros Biosciences AG / Key word(s): MiscellaneousKuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial 31.05.2022 / 07:00 Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planne.